LAUSR

Receptor tyrosine kinase c-Met is an important antitumor drug target. Triazolotriazine analogues 2–10 were prepared efficiently and evaluated the enzymatic and cellular c-Met activities. Brief structure–activity relationships of triazolotriazine core and CF2-quinoline part were investigated, leading to the discovery of compound 8 with nanomolar enzymatic c-Met activity, and subnanomolar MKN45 and EBC-1 cellular potencies. The proposed binding model of 8 and c-Met unraveled that two canonical hydrogen bonds and a π–π stacking interaction formed between the inhibitor and the ATP binding site of c-Met kinase domain, which accounted for its potent c-Met activities.